T-MSIS provider-level spending data, Jan 2018 – Dec 2024
Injection, ocrelizumab, 1 mg
Total Paid
$391.8M
$391,826,852
Beneficiaries
21K
20,729
Avg $/Claim
$16,045
Utilization
1.2 claims/bene
65 providers
Each dot is a state. X = average cost per claim. Y = total spending.
Drag to zoom into a region
| # | State | Total Paid▼ | Avg $/Claim | Claims | Beneficiaries | Providers |
|---|---|---|---|---|---|---|
| 1 | OH | $90.1M | $20,560 | 4,383 | 3,277 | 9 |
| 2 | CT | $86.5M | $17,347 | 4,986 | 4,162 | 4 |
| 3 | NY | $65.3M | $26,770 | 2,438 | 2,237 | 6 |
| 4 | MI | $24.7M | $18,375 | 1,346 | 1,226 | 5 |
| 5 | SC | $24.5M | $13,897 | 1,760 | 1,552 | 1 |
| 6 | MA | $19.6M | $7,895 | 2,481 | 2,228 | 5 |
| 7 | WA | $15.9M | $11,308 | 1,410 | 1,260 | 4 |
| 8 | NJ | $14.2M | $14,847 | 959 | 742 | 5 |
| 9 | PA | $11.4M | $6,419 | 1,774 | 1,655 | 6 |
| 10 | IL | $9.2M | $24,068 | 383 | 348 | 2 |
| 11 | VA | $5.8M | $18,368 | 314 | 262 | 3 |
| 12 | CA | $5.0M | $25,169 | 197 | 180 | 3 |
| 13 | AR | $4.0M | $8,505 | 474 | 299 | 1 |
| 14 | RI | $3.9M | $26,378 | 148 | 132 | 1 |
| 15 | KY | $3.7M | $17,040 | 220 | 177 | 4 |
| 16 | AZ | $3.6M | $12,655 | 281 | 229 | 2 |
| 17 | WI | $2.8M | $3,717 | 759 | 671 | 4 |
| 18 | ME | $644K | $22,200 | 29 | 29 | 1 |
| 19 | MD | $524K | $30,837 | 17 | 12 | 1 |
| 20 | IA | $431K | $7,069 | 61 | 51 | 1 |